FDA Announces Rare Disease Framework Initiative to Foster Consistent Review Approach Tailored to Unique Drug Development Considerations for Rare Diseases

Since Congress’s adoption of the 21st Century Cures Act, FDA has exercised enhanced flexibility with respect to the means by which rare-disease sponsors can show safety and effectiveness within the unique constraints of rare disease development. Even so, FDA has faced critiques that certain elements of the Agency are applying insufficient regulatory flexibility and that similarly situated applications may be treated differently depending on which team is involved. On October 14, 2026, FDA launched a new Rare Disease Framework Initiative to develop an updated approach to rare disease drug review “where advice and decision-making are consistently tailored to what evidence is reasonably attainable given the nature of the disease.”¹ FDA stated that the initiative—which is led by FDA’s Rare Disease Innovation Hub in partnership with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER), and the Center for Drug Evaluation and Research (CDER)—aims to “ensure scientific rigor without unnecessary demands that are infeasible” for rare diseases.²

In announcing the initiative, FDA recognized the profound unmet need among rare disease patients, noting that only 5% of rare diseases have an FDA-approved treatment as of 2025.³ In line with recent FDA statements,⁴ the Agency also emphasized that rare diseases present unique drug development challenges and considerations—for example, small patient populations, limited natural history data, and disease heterogeneity, all of which may impact clinical trial designs—which should be reflected in the Agency’s approach.⁵ While FDA noted that it has used a tailored regulatory approach reflecting rare disease-specific considerations on “many occasions,” it acknowledged that there remains a need for a “consistently utilized, cross-center approach” that provides greater clarity and predictability in rare disease regulatory decision-making for drug developers, patients, and researchers.⁶

FDA’s announcement and accompanying white paper did not name specific regulations, guidance, or other FDA policies that may undergo review as part of the Rare Disease Framework Initiative, but the Agency noted that it will “review existing policies, procedures, programs, guidances, and regulations addressing rare disease drug development” and will “implement and communicate . . . improvements.”⁷ Outcomes may include:

• Revisions to existing regulations or new regulations “to embed fit-for-purpose evidentiary standards into the legal foundation of the rare disease review process”;
• Revisions to existing guidance or new guidance “to provide clearer, more predictable direction on endpoints, statistical approaches, trial design, patient engagement, external expert consultation, and post-approval obligations in the rare disease context”; and
• Increased alignment within CDER and CBER “to improve consistency across review divisions and consolidate rare disease review expertise.”⁸

To inform the Rare Disease Framework Initiative, FDA plans to solicit feedback from rare disease patients, advocates, and industry. Planned opportunities for public input include a Rare Disease Framework Initiative Public Meeting scheduled for October 28, 2026, a Federal Register Request for Information, and sector-specific roundtables.⁹

The outcomes contemplated by the Rare Disease Framework Initiative theoretically could impact not only new drug development, but also drugs already under review. In practical terms, however, FDA’s announcement did not specify a timeline, and it remains to be seen how quickly these changes could be implemented.¹⁰ Certain changes—such as notice-and-comment rulemaking to revise regulations—could take years, while others—such as updates to guidance and internal Agency review processes—potentially could be implemented more quickly.

Ultimately, the Rare Disease Framework Initiative represents a clear, renewed Agency commitment to rare disease patients and an opportunity for rare disease patients, industry, and other stakeholders to engage in advocacy regarding how the Agency can best address rare disease patients’ needs.